Mostrar el registro sencillo del ítem
dc.contributor.author | Fernández-Ruiz, Mario | |
dc.contributor.author | Almendro-Vázquez, Patricia | |
dc.contributor.author | Carretero, Octavio | |
dc.contributor.author | Ruiz-Merlo, Tamara | |
dc.contributor.author | Laguna-Goya, Rocío | |
dc.contributor.author | San Juan, Rafael | |
dc.contributor.author | López-Medrano, Francisco | |
dc.contributor.author | Garcia-Rios, Estefani | |
dc.contributor.author | Mas-Lloret, Vicente | |
dc.contributor.author | Moreno-Batenero, Miguel | |
dc.contributor.author | Loinaz, Carmelo | |
dc.contributor.author | Andrés, Amado | |
dc.contributor.author | Perez-Romero, Pilar | |
dc.contributor.author | Paz-Artal, Estela | |
dc.contributor.author | Aguado, José María | |
dc.contributor.author | Octavio | |
dc.date.accessioned | 2022-05-06T12:40:01Z | |
dc.date.available | 2022-05-06T12:40:01Z | |
dc.date.issued | 2021-11-17 | |
dc.identifier.citation | Transplant Direct 2021 Nov 17;7(12):e794. | es_ES |
dc.identifier.issn | 2373-8731 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14309 | |
dc.description.abstract | Background: Severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) elicited by mRNA-based vaccines in solid organ transplant (SOT) recipients and its correlation with antibody responses remain poorly characterized. Methods: We included 44 (28 kidney, 14 liver, and 2 double organ) recipients who received the full series of the mRNA-1273 vaccine. SARS-CoV-2-CMI was evaluated at baseline, before the second dose, and at 2 wk after completion of vaccination by an ELISpot-based interferon-γ FluoroSpot assay using overlapping peptides covering the S1 domain. SARS-CoV-2 immunoglobulin G seroconversion and serum neutralizing activity against the spike protein were assessed at the same points by commercial ELISA and an angiotensin-converting enzyme-2/spike antibody inhibition method, respectively. Postvaccination SARS-CoV-2-CMI was compared with 28 healthcare workers who received the BNT162b2 vaccine. Results: Positive SARS-CoV-2-CMI increased from 6.8% at baseline to 23.3% after the first mRNA-1273 dose and 59.5% after the completion of vaccination (P < 0.0001). Lower rates were observed for immunoglobulin G seroconversion (2.3%, 18.6%, and 57.1%, respectively) and neutralizing activity (2.3%, 11.6%, and 31.0%). There was a modest correlation between neutralizing titers and the magnitude of SARS-CoV-2-CMI (Spearman's rho: 0.375; P = 0.015). Fifteen recipients (35.7%) mounted SARS-CoV-2-CMI without detectable neutralizing activity, whereas 3 (7.1%) did the opposite, yielding poor categorical agreement (Kappa statistic: 0.201). Rates of positive SARS-CoV-2-CMI among SOT recipients were significantly decreased compared with nontransplant controls (82.1% and 100.0% after the first dose and completion of vaccination, respectively; P < 0.0001). Kidney transplantation, the use of tacrolimus and prednisone, and the number of immunosuppressive agents were associated with lower cell-mediated responses. Results remained unchanged when 3 recipients with prevaccination SARS-CoV-2-CMI were excluded. Conclusions: Two-thirds of SOT recipients mounted SARS-CoV-2-CMI following vaccination with mRNA-1273. Notable discordance was observed between vaccine-induced cell-mediated and neutralizing humoral immunities. Future studies should determine whether these patients with incomplete responses are effectively protected. | es_ES |
dc.description.sponsorship | This work was supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181) and cofinanced by the European Development Regional Fund “A way to achieve Europe.” M.F.R. holds a research contract “Miguel Servet” (CP18/00073) and R.L.G. a research contract “Rio Hortega” (CM19/00120), both from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Lippincott Williams & Wilkins (LWW) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 34805496 | es_ES |
dc.format.volume | 7 | es_ES |
dc.format.number | 12 | es_ES |
dc.format.page | e794 | es_ES |
dc.identifier.doi | 10.1097/TXD.0000000000001246 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.1097/TXD.0000000000001246 | es_ES |
dc.identifier.journal | Transplantation Direct | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/null/Contratos Miguel Servet (2018)/CP18/00073 | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/null/Contratos Río Hortega (2019)/CM19/00120 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/COV20/00181 | es_ES |